QuidelOrtho Corporation provides various in vitro diagnostics products worldwide. The company's product portfolio covers a range of point-of-care tests for infectious diseases, critical cardiac health and autoimmune biomarkers, and clinical and at-home products to detect COVID-19. It provides visually-read lateral flow products in infectious disease and reproductive health; direct fluorescent antibodies in infectious disease and virology; micro-titer production with a focus on bone and complement pathway markets; fluorescent immunoassay products; molecular diagnostic products comprising Savanna, an integrated molecular diagnostic system; immunodiagnostics, clinical chemistry, and integrated testing systems to serve diagnostic labs of all sizes; immunodiagnostic donor screening systems and services that drive blood safety; pre-transfusion testing that automates blood bank workload with software to standardize operations, simplify tasks, and improve productivity; and Ortho Care services and informatics products. The company was founded in 1979 and is headquartered in San Diego, California.
QuidelOrtho Price Performance
NASDAQ:QDEL opened at $84.09 on Friday. QuidelOrtho has a 52 week low of $83.39 and a 52 week high of $180.06. The firm has a market cap of $5.63 billion, a price-to-earnings ratio of 3.56 and a beta of 0.03. The firm's 50-day simple moving average is $99.03 and its 200 day simple moving average is $101.75. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.94 and a current ratio of 1.73.
Analyst Ratings Changes
Several research analysts recently commented on the stock. StockNews.com upgraded shares of QuidelOrtho from a "hold" rating to a "buy" rating in a report on Friday, May 13th. UBS Group began coverage on shares of QuidelOrtho in a research report on Wednesday, July 20th. They set a "sell" rating and a $86.00 target price on the stock. Finally, JPMorgan Chase & Co. started coverage on shares of QuidelOrtho in a research note on Friday, June 17th. They set a "neutral" rating for the company. One analyst has rated the stock with a sell rating, one has given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, QuidelOrtho presently has an average rating of "Moderate Buy" and a consensus price target of $98.67.